文献速递内脏/肾动脉与血管畸形

急性肠系膜缺血逆行开放肠系膜支架置入技术与中期结果

Technical aspects and midterm results of retrograde open mesenteric stenting for acute mesenteric ischemia.
PubMed 文献 · J Vasc Surg · 2025-11-14

3年总体生存率59.7%,免于支架相关再干预率68.2%,一期通畅率81.3%,辅助一期通畅率87.6%。

要点

  • ROMS技术成功率88%,但院内死亡率高达31.2%,需严格筛选患者。
  • 30天支架相关并发症达26.3%,以支架闭塞最常见,需密切监测。
  • 3年一期通畅率81.3%、辅助一期通畅率87.6%,中期通畅性可接受。

核心结论

  • ROMS技术成功率与中期结果可接受,但死亡、肠切除及支架相关并发症发生率较高。
  • 支架相关并发症导致频繁再干预与额外死亡,可通过特定技术要点加以减轻。

研究设计与样本

  • 采用Kaplan-Meier时间-事件法分析3年总体生存率、免于再干预率、一期通畅率及辅助一期通畅率。

主要发现

  • 65例中27例(40.5%)有慢性肠系膜缺血病史,全部为肠系膜动脉闭塞性病变,累及肠系膜上动脉(原位血栓46例,狭窄>70%者19例)。
  • 总体技术成功率88%,肠切除率35.4%(23例),院内死亡率31.2%。
  • 30天支架相关并发症占26.3%,包括ROMS闭塞7例、肠系膜上动脉残余病变(夹层/血栓)4例、支架远端扭折2例、支架移位2例。
  • 平均随访24.9个月,3年总体生存率59.7%(95%CI 46.7%-70.5%),随访期间8例需支架相关再干预,3年免于支架相关再干预率68.2%(95%CI 50%-81%)。
  • 3年一期通畅率81.3%(95%CI 65.4%-90.4%),辅助一期通畅率87.6%(95%CI 72.3%-94.7%)。

临床怎么用

  • 对急性肠系膜缺血行ROMS应警惕高死亡率与肠切除风险,术前充分评估并做好术后监护。
  • 术后30天内重点监测支架闭塞、残余病变、扭折与移位,及时发现并处理以降低再干预率。

局限性

  • 为回顾性多中心研究,样本量65例,结果可能受选择偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Retrograde open mesenteric stenting (ROMS) may provide satisfactory initial results for the treatment of mesenteric ischemia. However, this procedure remains technically demanding and its complications may lead to significantly higher morbidity, mortality, and reinterventions rates in severely ill patients. This study aimed to report stent-related complications and midterm outcomes of ROMS for acute mesenteric ischemia (AMI). METHODS: Clinical data and outcomes of all consecutive patients treated with ROMS for AMI between February 2014 and December 2021 at three university hospitals were reviewed retrospectively. End points included technical success, in-hospital mortality, postoperative complications, stent-related complications, and reinterventions. Three-year overall survival, freedom from reintervention, primary patency, and assisted primary patency rates were analyzed using the Kaplan-Meier time-to-event method. RESULTS: Sixty-five patients presenting with AMI were included, of which 27 (40.5%) had a history of chronic mesenteric ischemia. All patients presented with mesenteric artery occlusive disease, involving the superior mesenteric artery (in situ thrombosis, n = 46; >70% stenosis, n =19). Overall technical success rate of the ROMS procedure in the cohort was 88%. The overall intestinal resection rate in the cohort was 35.4% (n = 23 patients). In-hospital mortality rate was 31.2%. Stent-related complications at 30 days were reported in 26.3% of patients, including ROMS occlusion (n = 7), residual superior mesenteric artery lesion (dissection/thrombus, n = 4), distal stent kinking (n = 2), and stent migration (n = 2). The mean follow-up duration was 24.9 months. The estimated 3-year overall survival rate for the cohort was 59.7% (95% confidence interval [CI], 46.7%-70.5%). Eight patients required additional stent-related reinterventions during follow-up, giving an estimate of freedom from stent-related reintervention at three years of 68.2% (95% CI, 50%-81%). The estimated three-year primary patency and assisted primary patency rates were 81.3% (95% CI, 65.4%-90.4%) and 87.6% (95% CI, 72.3%-94.7%), respectively. CONCLUSIONS: ROMS provides acceptable technical success rate and midterm outcomes but is associated with high mortality, bowel resection, and specific stent-related complication rates. Such complications, resulting in frequent reinterventions and additional mortality, could be mitigated by implementing specific technical tips.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Khayat N, Mage A, Ben Abdallah I, et al. Technical aspects and midterm results of retrograde open mesenteric stenting for acute mesenteric ischemia. J Vasc Surg. 2025. PMID: 41242624. doi:10.1016/j.jvs.2025.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。